Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GSK Spin-Off Launches KaNDy To Tackle Key Symptoms Of Menopause

Executive Summary

NeRRe Therapeutics has set up a new entity around a drug which it believes could be an effective alternative to hormone replacement therapy for hot flashes that may rapidly reduce debilitating sleep disturbance.

You may also be interested in...



Bayer Hopeful Of Sweet Success With KaNDy Buy

Bayer is paying $425m upfront to acquire KaNDy Therapeutics, whose CEO tells Scrip that the German group was always the preferred partner due to its long-standing commitment to women’s health.

Interview: KaNDy Menopause Therapy Hits Sweet Spot

Prospective partners will be impressed by data which shows that the UK company's once-daily oral treatment reduces hot flashes and night sweats and has also shown very rapid improvements in mood and sleep.

Investors Sweet On KaNDy Menopause Treatment

Armed with a fresh injection of £25m, the UK's KaNDy is about to begin Phase IIb trials of a dual mechanism therapy it believes will be a transformational treatment to tackle two key symptoms of the menopause, hot flashes and night time awakenings.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

OM016808

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel